Business context and reporting period
The supplied filing is Cyclacel Pharmaceuticals, Inc.’s unaudited Form 10-Q for the quarter ended June 30, 2023—not a filing for Bio Green Med Solution, Inc. Cyclacel is a clinical-stage biopharmaceutical company developing cancer drug candidates. Its primary programs are fadraciclib, a CDK2/9 inhibitor, and plogosertib, a PLK1 inhibitor.
Financial results and liquidity
Amounts below are in millions of dollars unless otherwise noted.
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Revenue | $0.373 | $0 | $0.373 | $0 |
| Research and development expense | $4.727 | $4.205 | $10.401 | $9.159 |
| General and administrative expense | $1.575 | $1.580 | $3.220 | $3.185 |
| Operating loss | $(5.929) | $(5.785) | $(13.248) | $(12.344) |
| Net loss | $(5.448) | $(4.575) | $(11.252) | $(8.683) |
| Net loss attributable to common shareholders | $(5.498) | $(4.625) | $(11.353) | $(8.784) |
| Loss per common share, basic and diluted | $(0.44) | $(0.46) | $(0.91) | $(0.87) |
The $0.373 million revenue in 2023 was reimbursement of clinical manufacturing costs for an investigator-sponsored study, not product sales. The filing does not report a meaningful operating margin for this development-stage business.
For the six months ended June 30, 2023, operating cash use was $8.166 million, investing cash use was $0.006 million, and financing cash use was $0.101 million. Cash declined $8.181 million to $10.164 million. The company received approximately $4.846 million in R&D tax credits during the period.
At June 30, 2023, current assets were $15.294 million, current liabilities $6.746 million, and working capital $8.548 million. Total assets were $16.442 million and total liabilities, including lease liability, were $6.812 million. The filing does not show conventional borrowings; lease liability was $0.066 million. Accumulated deficit was $417.409 million.
Material changes versus prior periods
- Six-month R&D expense rose $1.242 million, or 14%, led by higher fadraciclib program costs; G&A was broadly stable.
- Six-month net loss increased $2.569 million. Other income fell to $0.090 million from $1.539 million, largely because 2022 included $1.280 million of income related to a legacy asset purchase agreement; 2023 included $0.058 million.
- Cash and cash equivalents fell from $18.345 million at December 31, 2022 to $10.164 million at June 30, 2023. The company had $29.077 million at June 30, 2022.
- Common shares outstanding were 12,642,822 at June 30, 2023, compared with 12,539,189 at year-end 2022. Potentially dilutive securities were excluded from loss-per-share calculations as anti-dilutive.
Outlook, risks and unusual items
- Going concern: Management stated that available cash was expected to fund operations through the end of 2023; not incurring discretionary spending could extend the runway into Q2 2024. The filing concludes substantial doubt exists about the company’s ability to continue as a going concern for at least 12 months from issuance. Planned equity or debt financing and partnerships are uncertain.
- Clinical programs: At the filing date, 28 patients had been treated in the fadraciclib Phase 1/2 study and 14 in the plogosertib study; no dose-limiting toxicities had been observed in the latter study’s dose-escalation levels. The company reported a temporary halt of its Phase 1/2 study in hematological malignancies while progressing studies in solid tumors and lymphomas.
- Spending outlook: Management expected 2023 R&D and G&A expenses to be lower than in 2022. Future results remain dependent on clinical progress, financing availability, and R&D tax-credit eligibility.
- Potential rescission exposure: The company reclassified $4.494 million received for 3,117,100 shares sold after an associated shelf registration statement expired. Certain shareholders may have rescission rights; no claims or demands had been received by June 30, 2023. The shares remained treated as issued and outstanding for financial reporting.
- The company said there were no material changes to previously reported risk factors and no legal proceedings. Disclosure controls were assessed as effective as of June 30, 2023.
Important facts for investors to verify
- Confirm the issuer identity: this filing is for Cyclacel Pharmaceuticals, Inc., not Bio Green Med Solution, Inc.
- Monitor cash burn, financing plans, and whether the stated cash runway assumptions remain valid given the going-concern warning.
- Track clinical-trial enrollment, safety, efficacy signals, and the status of the temporarily halted hematological study.
- Assess possible shareholder rescission claims related to the $4.494 million share-sale reclassification and any effects on liquidity or equity.
- Verify future R&D tax-credit receipts and dilution from equity financing, options, warrants, and preferred securities.